We'll know more about the company's medium-term prospects by the end of the year.

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but companies like Amgen and AbbVie with broad product portfolios and multi-year pipeline ...

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the must-buy small cap stocks to buy. On April 13, Vir Biotechnology, Inc.

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...